Log in
Enquire now
‌

US Patent 11945869 PD-1 single domain antibodies and therapeutic compositions thereof

Patent 11945869 was granted and assigned to Inhibrx on April, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Current Assignee
Inhibrx
Inhibrx
0
Date Filed
November 11, 2021
0
Date of Patent
April 2, 2024
0
Patent Applicant
Inhibrx
Inhibrx
0
Patent Application Number
17524016
0
Patent Citations
‌
US Patent 7728114 Anti-CD3 antibodies and methods of use thereof
0
‌
US Patent 7959925 Trimeric OX40-immunoglobulin fusion protein and methods of use
0
‌
US Patent 7994289 Humanized anti-CD3 antibodies
0
‌
US Patent 7998469 Protease resistant interferon beta mutants
0
‌
US Patent 8044178 Anti-5T4 antibodies and uses thereof
0
‌
US Patent 8052964 Interferon-β mutants with increased anti-proliferative activity
0
‌
US Patent 9006399 Anti-OX40 antibodies and methods of using the same
0
‌
US Patent 9035026 Anti-CD16 binding molecules
0
‌
US Patent 9605084 Heterodimeric proteins
0
‌
US Patent 9644016 Soluble notch receptor proproteins and methods of use thereof
0
•••
Patent Inventor Names
Angelica N. Sanabria
0
Rajay A. Pandit
0
John C. Timmer
0
Florian Sulzmaier
0
Brendan P. Eckelman
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11945869
0
Patent Primary Examiner
‌
Amy E Juedes
0
CPC Code
‌
C07K 16/2815
0
‌
C07K 16/30
0
‌
C07K 16/2818
0
‌
C07K 16/2812
0
‌
C07K 16/2866
0

Find more entities like US Patent 11945869 PD-1 single domain antibodies and therapeutic compositions thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.